Search
Taysha Gene Therapies Inc
TSHAAdd to Watchlist
4.910USD
0.0000.00%
Close 09-23 16:00（ET）
1.57BMarket Cap
LossP/E TTM
Taysha Gene Therapies Inc (TSHA) Stock Price Target & Forecast
Analyst Rating
Based on 12 analysts giving stock ratings to Taysha Gene Therapies Inc in the past month.
Buy
4 Strong Buy
8 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
13.000USD+151.94%
TSHA Analyst Recommendation Trends
In the current month, TSHA has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TSHA average Analyst price target in the last month is 13.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
4
4
4
4
4
4
8
8
9
9
10
10
10
10
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
12
13
13
14
14
14
14
TSHA Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, TSHA EPS is projected to reach -0.130 in FY2026Q3, following reported EPS of -0.126 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.10
-0.10
-0.12
-0.13
-0.13
Actual
-0.08
-0.12
-0.13
--
--
Surprise
+18.94%
-18.43%
-8.43%
--
--
FAQs
What is Taysha Gene Therapies Inc's expected revenue for the next quarter?
Taysha Gene Therapies Inc's expected revenue is 618.18K.
What is Taysha Gene Therapies Inc's price target?
Analysts forecast that Taysha Gene Therapies Inc's price target is USD 13.00, with the highest forecast at USD 19.00 and the lowest forecast at USD 9.00.
How have Taysha Gene Therapies IncTSHA's recent earnings per share performed?
The market expectation was USD -0.13, while Taysha Gene Therapies IncTSHA's earnings per share (EPS) for the previous quarter was USD -0.12. EPS for the next quarter is expected at USD -0.13.
What is the analyst rating for Taysha Gene Therapies Inc?
Based on the ratings of Taysha Gene Therapies Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.